By Richard Asinof
WOONSOCKET – MultiCell Technologies Inc. has announced a new collaboration with Genisphere LLC to collaborate on the development of a new nanopartical treatment for liver cancer.
The treatment will use MultiCell’s MCT-485, a noncoding double-stranded micro RNA, which has demonstrated oncolytic and immune stimulating activity in in vitro models of heptocellular carcinoma, the most common form of primary liver cancer.
MultiCell and Genisphere will investigate the use of Genisphere’s patented 3DNA Dendrimer nanoparticle drug delivery technology to enable the targeted delivery of MCT-485 to the tumor and away from normal tissues.
Hepatocellular carcinoma remains an unmet medical need, and today's approaches for treatment are of limited efficacy, according to the news release.